Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
112
resultados
Última actualización
10/09/2026 [10:34:00]
Resultados 50 a 75 de 112
Resumen de: WO2025027496A1
A custom tool for forming a dental restoration in a mouth of a patient includes a one-piece mold body providing for a customized fit with at least one tooth of the patient, the one-piece mold body including an occlusal portion forming an occlusal surface corresponding with an occlusal surface of the tooth, a mesial proximal portion forming a mesial proximal surface corresponding with a mesial proximal surface of the tooth, and a distal proximal portion forming a distal proximal surface corresponding with a distal proximal surface of the tooth. The mold body is configured to combine with the tooth of the patient to form a mold cavity encompassing missing tooth structure of the tooth. The occlusal portion, the mesial proximal portion, and the distal proximal portion are based on three-dimensional scan data of the mouth of the patient.
Resumen de: US20260256423A1
A method includes receiving data for an episode stored by a medical device of a patient. The episode is associated with a period of time. The data includes an electroencephalogram or data derived from neural activity in the brain sensed by the medical device during the period of time. One or more machine learning models are applied to the data and are configured to output a respective likelihood value for each of a plurality of tremor type classifications. The method further includes, based on the application of the one or more machine learning models to the episode data, deriving, for each of the tremor type classifications, class activation data indicating varying likelihoods of the classification over the period of time; and displaying a graph of the varying likelihoods of the tremor type classifications over the period of time.
Resumen de: US20260256842A1
0000 The present disclosure provides thymic cells, thymic organoids, and animal models comprising such thymic cells and thymic organoids. It also provides methods for inducing differentiation of pluripotent stem cells into definitive endoderm (DE), anterior foregut endoderm (AFE), ventral pharyngeal endoderm (VPE), thymic epithelial progenitor (TEP) cells, thymic epithelial cells (TECs) and thymic organoids in vitro and in vivo.
Resumen de: US20260256654A1
0000 The present invention is directed to a tablet dispenser. The tablet dispenser includes: a discharge part sealing unit positioned beneath a plurality of tablet discharge devices each including a discharge part for discharging stored tablets, and provided with a plurality of openings; and a tablet collection module positioned beneath the discharge part sealing unit. When the discharge part sealing unit is moved in a first planar direction, it blocks the discharge parts to spatially separate the plurality of discharge parts from the tablet collection module. When the discharge part sealing unit is moved in a second planar direction opposite the first planar direction, it positions the openings in the same lines as the corresponding discharge parts to allow the plurality of discharge parts to spatially communicate with the tablet collection module.
Resumen de: US20260256591A1
0000 The present technology provides patient-specific vertebral implants. The implants can include a cage having a geometry contoured to mate with an inferior surface of a superior vertebra and a superior surface of an inferior vertebra at a first target position. The implants can also include a plate having a geometry contoured to mate with an identified anatomical structure at a second target position. The cage and plate can be coupled in a predetermined three-dimensional orientation that simultaneously permits the cage to occupy the first target position and the plate to occupy the second target position when the implant is implanted.
Resumen de: US20260260729A1
0000 Systems and methods are provided for identifying therapeutic zones where there is glycemic dysfunction of a specific type that can be addressed by making strategic changes to behavior and/or therapy parameters. Systems and methods described herein evaluate large historical data sets to: identify a therapeutic zone or zones with glycemic dysfunction that are most readily addressable; quantify the glycemic impact of a plurality of different therapeutic adjustments in terms of either adjustments to historical doses or the parameters of a prospective dosing strategy to determine the highest possible improvement; and/or identify patient dosing strategies to provide therapy recommendations adapted for the patient’s preferred behavioral dosing strategy.
Resumen de: US20260256413A1
0000 This disclosure describes systems, apparatuses, and techniques that use of multiple sensing modalities (multimodal sensing) in parallel to improve the detection, classification, and evaluation of seizures in subjects (e.g., mammalian subjects, such as humans). In some implementations, a wearable device includes a flex sensor configured, an inertial motion unit (IMU), and a plurality of surface electromyogram (sEMG) electrodes configured to be placed approximate to a muscle of a subject. The device also includes a microprocessor. The operations performed by the microprocessor include determining multimodal movement data of the muscle, where the multimodal movement data specifies at least an acceleration associated with movement of the muscle, an angular velocity associated with movement of the muscle, and sEMG activity associated with the movement of the muscle. The operation further includes determining whether the multimodal movement data indicates a possible seizure, and provide data based on the determination for output.
Resumen de: US20260256701A1
0000 A process system and method for the making of articles, using an omnidirectional magnetic movement system with a transport surface and fabrication modules having a formation surface that can be transported omnidirectionally over the transport surface under the control of a movement controller. An article forming system provides process unit operations for forming articles onto the formation surface as the fabrication modules are moved asynchronously between a plurality of processing positions on the transport surface, and features a depositing device for placing a construction material onto the formation surface and one or more processing devices to form the construction material into the article.
Resumen de: US20260256407A1
In some aspects, the present disclosure describes a method of predicting an expected treatment outcome of a subject, comprising administering a gamma oscillation-inducing non-invasive sensory stimulus to the subject, measuring a response from the subject, and predicting, using a machine learning algorithm, the expected treatment outcome of the subject based at least partially on the measured response. In some aspects, the present disclosure also provides methods for personalizing gamma therapy treatment by adjusting parameters associated with the gamma oscillation-inducing non-invasive sensory stimulus based on a subject's response to the gamma oscillation-inducing non-invasive sensory stimulus.
Resumen de: US20260256430A1
0000 Some embodiments of the disclosure describe an evaluation system based on analyte data including a memory storing a program, a display, and a processor. In some examples, the processor is configured to: receive analyte data during a predetermined time period from an object to be tested, acquire a plurality of analyte indicators different from each other based on the analyte data, normalize the plurality of analyte indicators to a predetermined range to acquire a plurality of normalized analyte indicators, plot a polygon pattern corresponding to the analyte data during the first time period as a target polygon pattern, plot a polygon pattern corresponding to the analyte data during the second time period as a reference polygon pattern, and take a line segment between a vertex and a center point as an axis, and display the target polygon pattern and the reference polygon pattern.
Resumen de: US20260260724A1
0000 Systems, devices, user interfaces, and methods for managing patient conditions. A system for monitoring and/or managing a patient suffering from a brain condition may include a controller obtaining and/or storing data related to one or more monitored patient parameters contributing to the brain condition of the patient and displaying values of the one or more monitored patient parameters in trend lines over time on a user interface. The displayed trend lines may represent values of ventricular CSF volume, values of IVH volume, total ventricular volume in the brain, and/or values of other suitable parameters. The data related to the one or more monitored patient parameters may include images of the patient’s brain and/or data derived from images of the patient’s brain and/or suitable patient data.
Resumen de: US20260260476A1
A method for locating an anatomical landmark includes obtaining an ultrasound image of an anatomical area from an ultrasound imaging device and inputting the ultrasound image into a first stage of a convolutional neural network where the first stage configured to determine a key-point location of the anatomical area. The method also includes generating, for the key-point location, a cropped region of the ultrasound image and inputting the cropped region into a second stage of the convolutional neural network, where the second stage is configured to locate the anatomical landmark of the anatomical area. Then, outputting a location of the anatomical landmark.
Resumen de: US20260260730A1
A method of administering insulin includes receiving scheduled glucose time intervals and obtaining glucose data of a patient that includes glucose measurements, glucose times, and insulin dosages previously administered by the patient. The method also includes applying a set of filters to identify which of the glucose measurements associated with at least one of the scheduled time intervals are usable and which of the glucose measurements associated with the at least one scheduled time interval are unusable. The method also includes aggregating the glucose measurements associated with the at least one scheduled time interval identified as usable to determine a representative aggregate glucose measurement and determining a next recommended insulin dosage for the patient based on the representative aggregate glucose measurement and the insulin dosages previously administered by the patient.
Resumen de: AU2026216825A1
An apparatus, system and method for regulating fluid flow are disclosed. An apparatus for infusing fluid into a patient includes a housing, a tube-contact member, a rotating arm, and a tube-retention cover. The housing has an opening on a front side of the housing. The opening is sized to receive a drip chamber having an inlet tube and an outlet tube. The tube-contact member contacts one of the inlet tube and the output tube of the drip chamber when inserted into the opening. The rotating arm is coupled to the tube-contact member and is configured to rotate along an axis. The tube-retention cover is configured to close when the drip chamber is initially loaded into the opening. tube and an outlet tube. The tube-contact member contacts one of the inlet tube and ug u g t u b e a n d a n o u t l e t t u b e h e t u b e - c o n t a c t m e m b e r c o n t a c t s o n e o f t h e i n l e t t u b e a n d
Resumen de: US20260256181A1
The present invention refers to a method for producing a nutraceutical delivery system. The method comprises the steps of screen-printing a base paste, and curing the base paste. The method furthermore comprises the steps of screen-printing a first paste being separate to the base paste, and curing said first paste.
Resumen de: US20260257029A1
Methods and apparatus provide communications among respiratory therapy device (“TD”), server and intermediary (e.g., a control device (“CTLD”) for the therapy device) to improve security. More secure communication channel(s) may be established using shared secrets derived with different channels. The communications may include transmitting therapy data from TD to server for authentication. The CTLD may receive the data and a nonce from a server. The CTLD receives from the TD a signing key dependent on the nonce and a secret shared by TD and server. The CTLD generates an authorisation code with received therapy data and the key for authentication of the data by the server upon its receipt of the code and data. The server computes (1) a key from the nonce and the secret known to TD, and (2) another authorisation code from received therapy data and the key. Data authentication may involve comparing received and computed codes.
Resumen de: US20260256592A1
0000 A system and method for improving upon an ability of a surgeon to repair traumatic bone injury using new materials, components, and structures. A structure may be used as an implant or a component of an external fixator for a fractured long bone with that structure having anisotropic and viscoelastic properties, such as through additive manufacturing techniques.
Resumen de: WO2026183490A1
This disclosure describes a method for altering the proteome of a diseased heart, organ or tissue by contacting it with extracellular matrix (ECM) particles derived from decellularized 3D microtissues. In an example, the process involves restoring the normal ratio of collagen levels, modulating immune responses, improving mitochondrial function, and/or mitigating the effects of TGF-Beta, a growth factor associated with fibrosis. The ECM particles can be produced from human mesenchymal stem cells and retain bioactive components and structural properties of native tissue. Additionally, the disclosure outlines a composition for treating a diseased organ using these ECM particles, which are treated to enhance crosslinking, stability, injectability, and compatibility with patients.
Resumen de: WO2026180764A1
The invention relates to a bioink for 3D printing of a scaffold (1) suitable for corneal tissue regeneration, composed of sodium alginate, aldehyde hyaluronic acid, N,O-carboxymethyl chitosan and collagen I, where the collagen I undergoes a preliminary neutralisation process using sodium hydroxide. The present invention also describes a method for the 3D printing of a scaffold (1) suitable for corneal tissue regeneration and a method for sterilising same using ethylene oxide (EtO).
Resumen de: US20260259290A1
A method includes receiving at a protocol optimizer an electronic medical record for the subject, wherein the electronic medical record includes a scan order for scanning a region of interest of the subject for a patient specific clinical indication with a magnetic resonance scanner. The method also includes utilizing the protocol optimizer to automatically access one or more initial protocols specific to the patient specific clinical indication from radiology guidelines and/or a protocol library. The method further includes generating with the protocol optimizer one or more optimized protocols from the one or more initial protocols for performing an acquisition including a three-dimensional (3D) acquisition of 3D image data of the region of interest of the subject, wherein the protocol optimizer is configured to reduce a number of scans for each contrast that is required by the patient specific clinical indication over the region of interest along multiple planes.
Resumen de: US20260256403A1
Systems and methods include approaches for calculating a relative timing value for respective beats associated with a rhythm classification, determining that respective relative timing values for a first set of the beats are within a first range of prematureness, and displaying time series cardiac data of the first set of the beats in a first window of a user interface.
Resumen de: US20260256395A1
A computer system receives sensor data from sensors configured to measure a user's neurophysiological response to verbal stimuli in the form of an identified emotion presented to the user and visual stimuli in the form of cosmetic colors presented to the user via a user interface; displays representations of available cosmetic colors to the user; receives user input indicating selection of a candidate cosmetic color from among the available cosmetic colors displayed; displays to the user an avatar wearing a virtual cosmetic of the candidate cosmetic color; receives user rating data responsive to display of the avatar wearing the virtual cosmetic of the candidate cosmetic color; and determines whether the candidate cosmetic color is associated with the identified emotion based on the user rating data and the sensor data. The sensors may include brain activity, electrodermal activity, eye tracking, and/or heart activity sensors.
Resumen de: WO2026183135A1
Fetal electrocardiogram (ECG) information and fetal oximetry information may be used, in combination, to determine one or more indicators, or predictions, of fetal wellness, blood oxygen saturation, and/or heartrate. At times, the fetal ECG and fetal oximetry information may be input into a fetal health model to determine and/or predict fetal wellness and/or trends in fetal wellness over time. In some embodiments, the fetal ECG and fetal oximetry information may be obtained via a single, combined, device configured to obtain and/or measure the fetal ECG and fetal oximetry information via direct contact with a fetus. Additionally, or alternatively, fetal oximetry information may be measured via a transabdominal fetal oximetry sensor and/or transcervical device configured to be positioned in the vagina and contact the cervix.
Resumen de: WO2026182227A1
Provided is a technology enabling reduction of administrator burden and enabling timely response for prevention of heat stroke. A WBGT value acquisition unit 51 acquires a WBGT value from a WBGT measurement device 4. A worker site information acquisition unit 52 acquires, from an administrator terminal 2, elicited information such as physical condition when reporting to work, medical history, work intensity, clothing, and heat acclimatization, and acquires, from a portable worker terminal 3, vital information such as heart rate, blood oxygen saturation, and activity level. A correction value calculation unit 53 calculates a correction value through AI analysis. An individual worker reference value calculation unit 54 calculates a corrected WBGT reference value for each worker by using the correction value to perform an operation on a WBGT reference value. A heat stroke risk value calculation unit 55 calculates a heat stroke risk value from the difference between the WBGT value and the corrected WBGT reference value.
Nº publicación: WO2026180968A1 03/09/2026
Solicitante:
COCHLEAR LTD [AU]
COCHLEAR LIMITED
Resumen de: WO2026180968A1
A method including executing an automatic evaluation of data residing on a computing system pertaining to a specific medical device. The method comprising obtaining access to a computing system, and via the computing system, obtaining access to data based on medical device settings and/or phenomena recorded in association with the medical device and executing an automated evaluation of the accessed data and gauging efficacy of the medical device based on results of the automated evaluation.
BOPI
Sede Electrónica
